Show simple item record

dc.contributor.authorJacobson, Allan
dc.contributor.authorSpatrick, Phyllis
dc.contributor.authorHe, Feng
dc.date2022-08-11T08:09:18.000
dc.date.accessioned2022-08-23T16:25:53Z
dc.date.available2022-08-23T16:25:53Z
dc.date.issued2007-05-03
dc.date.submitted2015-08-11
dc.identifier.doi10.13028/M2MW2F
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36443
dc.description<p>Legend is included on first worksheet of spreadsheet.</p>
dc.description<p>Methodology for RNA analysis: Quantitative real-time PCR was performed using primers for LUC and dystrophin mRNAs, with the levels of 18S rRNA and GAPDH mRNA serving as normalization factors for the amount of starting material. Northern blot analysis was performed using probes specific to LUC mRNA, with the level of GAPDH mRNA serving as a control for loading. High density oligonucleotide arrays (Affymetrix U133+, 2.0), containing 54,675 probe sets/chip) were used to analyse expression profiles of PTC124-treated, gentamicin-treated and untreated HEK293 cells. cRNA sample preparation, array hybridization and scanning followed protocols recommended by the manufacturer (<a href="http://www.affymetrix.com/estore/" target="_blank" title="http://www.affymetrix.com/estore/">http://www.affymetrix.com/estore/</a>). The hybridization intensity (signal) of each transcript was determined using the Affymetrix Microarray Suite 5.0 software package. Intensity values were scaled such that the overall fluorescence intensity of each array was equivalent. Scaling factors for each experimental set varied by less than 20%. Transcript levels specifically enhanced or reduced by drug treatment were identified by applying several stringent standards to the raw data, including: (a) the signal values of a transcript in the treated and untreated samples had to have a minimal level of at least 26 units and a relative change of at least twofold; (b) these changes had to be reproducible in five of the six independent replicate experiments; and (c) these changes had to demonstrate statistically significant P-values ≤ 0.05 in a group t-test. The GeneSpring (version 7; http://www.silicongenetics.com) and GENECLUSTER (version 1.0; http://www-genome.wi.mit.edu) software packages were used to identify transcripts that were differentially expressed.</p>
dc.description.abstractManuscript abstract: Nonsense mutations promote premature translational termination and cause anywhere from 5-70% of the individual cases of most inherited diseases. Studies on nonsense-mediated cystic fibrosis have indicated that boosting specific protein synthesis from less than 1% to as little as 5% of normal levels may greatly reduce the severity or eliminate the principal manifestations of disease. To address the need for a drug capable of suppressing premature termination, we identified PTC124-a new chemical entity that selectively induces ribosomal readthrough of premature but not normal termination codons. PTC124 activity, optimized using nonsense-containing reporters, promoted dystrophin production in primary muscle cells from humans and mdx mice expressing dystrophin nonsense alleles, and rescued striated muscle function in mdx mice within 2-8 weeks of drug exposure. PTC124 was well tolerated in animals at plasma exposures substantially in excess of those required for nonsense suppression. The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.
dc.format.medium.xls (24MB)
dc.language.isoen_US
dc.publisherJacobson Lab, University of Massachusetts Medical School
dc.relation<p>This dataset (.xls file, 24 MB) is the primary RNA analysis data for the following published study: Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. <a href="http://dx.doi.org/10.1038/nature05756" target="_blank" title="PTC124 targets genetic disorders caused by nonsense mutations">PTC124 targets genetic disorders caused by nonsense mutations</a>. Nature. 2007 May 3;447(7140):87-91. Epub 2007 Apr 22. doi:10.1038/nature05756. PubMed PMID: 17450125.</p>
dc.subjectBiochemistry, Biophysics, and Structural Biology
dc.subjectCellular and Molecular Physiology
dc.subjectChemicals and Drugs
dc.subjectCongenital, Hereditary, and Neonatal Diseases and Abnormalities
dc.subjectGenetics
dc.subjectMolecular Genetics
dc.titleData from: PTC124 Targets Genetic Disorders Caused by Nonsense Mutations
dc.typeDataset
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/maps_data/2
dc.identifier.contextkey7444224
html.description.abstract<p>Manuscript abstract: Nonsense mutations promote premature translational termination and cause anywhere from 5-70% of the individual cases of most inherited diseases. Studies on nonsense-mediated cystic fibrosis have indicated that boosting specific protein synthesis from less than 1% to as little as 5% of normal levels may greatly reduce the severity or eliminate the principal manifestations of disease. To address the need for a drug capable of suppressing premature termination, we identified PTC124-a new chemical entity that selectively induces ribosomal readthrough of premature but not normal termination codons. PTC124 activity, optimized using nonsense-containing reporters, promoted dystrophin production in primary muscle cells from humans and mdx mice expressing dystrophin nonsense alleles, and rescued striated muscle function in mdx mice within 2-8 weeks of drug exposure. PTC124 was well tolerated in animals at plasma exposures substantially in excess of those required for nonsense suppression. The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.</p>
dc.identifier.submissionpathmaps_data/2
dc.contributor.departmentDepartment of Microbiology and Physiological Systems


Files in this item

Thumbnail
Name:
PTC124_paper.xls
Size:
22.87Mb
Format:
Microsoft Excel

This item appears in the following Collection(s)

Show simple item record